Peptest® webinar – reimagining reflux diagnosis

April 30, 2025

Join us for a live webinar on the 14th of May 2025, hosted by Andrew Woodcock, Chief Scientific Officer at RD Biomed. This session will explore Peptest®, our non-invasive, saliva-based test that uses lateral flow technology to detect pepsin, a key biomarker of gastric reflux.

During the webinar, we’ll take a closer look at the development of Peptest, its clinical utility in helping to diagnose conditions such as laryngopharyngeal reflux (LPR), and its role in primary and specialist care settings. You’ll also gain insight into how this diagnostic tool supports post-treatment monitoring and improves overall patient outcomes.

Whether you’re a clinician, ENT specialist, speech and language therapist (SLT) or a clinician involved in reflux management, this is a valuable opportunity to discover how Peptest is helping to transform reflux diagnostics.

Register today to secure your place!

 


About BIOHIT HealthCare

BIOHIT HealthCare is a Finnish biotech company, headquartered in Helsinki, that specialises in the development, manufacture and distribution of kits and assays for the screening, diagnosis and monitoring of digestive diseases. Its core disease focus areas include stomach health and dyspepsia, reflux and acid dysregulation, Inflammatory Bowel Disease (IBD), functional gastrointestinal disorders (FGID), Irritable bowel syndrome (IBS), and gut microbiota dysbiosis. Innovating for Health www.biohithealthcare.co.uk

Recent Posts

How gluten immunogenic peptide testing fits into coeliac care pathways

March 30, 2026
GlutenDetect tests from BIOHIT determine gluten exposure

Gluten Immunogenic Peptide tests for coeliac patients

March 19, 2026

Connecting IBD care at University Hospital Southampton

December 4, 2025

Improving paediatric reflux care with objective, non-invasive diagnostics

November 18, 2025